Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Jiangsu Hengrui Pharmaceuticals Co., Ltd.
江蘇恒瑞醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1276)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to the disclosure requirements under Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

According to the relevant regulations of the People's Republic of China, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (the "**Company**") had published an announcement on the website of the Shanghai Stock Exchange (www.sse.com.cn). The following is a translation of the abovementioned announcement solely for reference only. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
江蘇恒瑞醫藥股份有限公司
Mr. Sun Piaoyang
Chairman

Shanghai, PRC
November 12, 2026

As at the date of this announcement, the Board comprises: (i) Mr. Sun Piaoyang, Mr. Dai Hongbin, Ms. Feng Ji, Mr. Zhang Lianshan, Mr. Jiang Frank Ningjun and Mr. Sun Jieping as executive Directors; (ii) Ms. Guo Congzhao as non-executive Director; and (iii) Mr. Lou Liguang, Mr. Zeng Qingsheng, Mr. Sun Jinyun and Mr. Chow Kyan Mervyn as independent non-executive Directors.

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Announcement in Relation to the Approval for Drug Registration

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein.

Recently, Beijing Suncadia Pharmaceuticals Co., Ltd., a subsidiary of Jiangsu Hengrui Pharmaceuticals Co., Ltd. (江蘇恒瑞醫藥股份有限公司) (the "Company"), received a notice from the National Medical Products Administration (the "NMPA") approving the marketing of the Company's self-developed Class 1 new drug, Rivocibart Injection. The relevant information is hereby announced as follows:

I. Basic Information of the Drug

Drug Name: Rivocibart Injection (Subcutaneous Injection)

Dosage Form: Injection

Strength: 300 mg (2 mL)/unit (pre-filled auto-injector pen)

Registration Category: Therapeutic Biological Product Class 1

Acceptance No.: CXSS2600019

Prescription Drug/Over-the-Counter Drug: Prescription drug

Approved Indications: This product can be used in combination with a low-fat diet and other lipid-lowering drugs to treat homozygous familial hypercholesterolemia (HoFH) in adults and adolescents aged 12 years and older to reduce low-density lipoprotein cholesterol (LDL-C) levels.

II. Other Information of the Drug

HoFH is a severe, life-threatening rare inherited metabolic disease.[2] Because of

loss or severe impairment of low-density lipoprotein receptor (LDL-R) function, the body loses or significantly reduces its ability to clear LDL-C from circulation, and patients have extremely elevated LDL-C levels from birth. LDL-C levels can usually reach up to 15 mmol/L in untreated patients.[3] This disease progresses rapidly, and its main clinical characteristics include skin and/or tendon xanthomas and early-onset atherosclerotic cardiovascular disease (ASCVD). If no standard treatment is given in time, patients may develop ASCVD before the age of 18 and die of coronary heart disease before the age of 30.[2] At present, the mechanism of action of mainstream lipid-lowering drugs depends on the LDL-R pathway to varying degrees, and the efficacy in HoFH patients who have had loss or impairment of LDL-R function is limited.[3] In addition, other treatment options, such as plasma exchange and liver transplantation, also face practical challenges such as poor accessibility and heavy burden.

Rivocibart Injection is an angiopoietin-like protein 3 (ANGPTL3) monoclonal antibody self-developed by the Company. It inhibits the activity of ANGPTL3, thereby reducing the levels of triglycerides (TG) and LDL-C in serum. This approval was based on a randomized, double-blind, placebo-controlled phase III clinical study (SHR-1918-301) in patients with HoFH aged ≥12 years, and the study results were presented in a Late-Breaking Science session at the European Society of Cardiology (ESC) Congress 2026.[1]

At present, the same-target drug EVKEEZA® (evinacumab-dgnb) of Regeneron has been approved for marketing abroad. According to the EvaluatePharma database, the global sales of the above product were approximately USD 216 million in 2025. As of now, the cumulative R&D investment in projects related to Rivocibart Injection amounts to approximately RMB 302.9 million (unaudited).

III. Risk Warning

The Company places great importance on drug R&D and strictly controls quality and safety throughout drug R&D, manufacturing, and sales processes. However, upon obtaining approval letter, the drug's production and sales may be subject to uncertainties. Investors are kindly advised to be prudent in investment decisions, paying attention to the risks involved.

Notice is hereby given.

Board of Directors of Jiangsu Hengrui Pharmaceuticals Co., Ltd.

November 12, 2026

1. Peng DQ, et al. ESC Congress 2026, LBA-7213.
2. Chinese Society of Laboratory Medicine of the Chinese Medical Association, et al. Chinese Expert Consensus on Early Screening and Management of Homozygous Familial Hypercholesterolemia (2024). Chinese Journal of Laboratory Medicine. 2024; 47(10): 1126-1138.
3. Jiang L, et al. Homozygous familial hypercholesterolemia in China: Genetic and clinical characteristics from a real-world, multi-center, cohort study. J Clin Lipidol. 2022 May-Jun; 16(3): 306-314.